Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11939
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCarter, Hannah Een
dc.contributor.authorZannino, Dianaen
dc.contributor.authorJohn Simes, Ren
dc.contributor.authorSchofield, Deborah Jen
dc.contributor.authorHoward, Kirstenen
dc.contributor.authorZalcberg, John Ren
dc.contributor.authorPrice, Timothy Jen
dc.contributor.authorTebbutt, Niall Cen
dc.date.accessioned2015-05-16T01:34:23Z
dc.date.available2015-05-16T01:34:23Z
dc.date.issued2013-11-08en
dc.identifier.citationEuropean Journal of Cancer (oxford, England : 1990) 2013; 50(3): 535-43en
dc.identifier.govdoc24215848en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11939en
dc.description.abstractBased on the clinical data, bevacizumab has been approved in Australia and globally for the treatment of advanced colorectal cancer. However, limited evidence exists for its cost-effectiveness. The purpose of this study was to evaluate the cost effectiveness of adding bevacizumab to capecitabine monotherapy in patients with metastatic colorectal cancer, using data from the prospective economic evaluation conducted alongside the MAX trial.Individual patient level data on resource use and progression free survival were prospectively collected in the phase III MAX trial. Resource use data were collected for the period between randomisation and disease progression, and unit costs were assigned from the perspective of the Australian health care funder. Effectiveness was measured in quality adjusted progression free survival years, with utility scores obtained from both the community valued EQ-5D questionnaire and the patient valued UBQ-C questionnaire. Progression free survival was used as a secondary effectiveness measure.The addition of bevacizumab to capecitabine monotherapy cost approximately $192,156 (95% confidence interval [CI], $135,619 to $326,894) per quality adjusted progression free survival year gained when using publicly listed pharmaceutical prices and utility values from the EQ-5D questionnaire. This decreased to $149,455 (95% CI, $100,356 to $245,910) when values from the UBQ-C questionnaire were applied. The incremental cost per progression free survival year was $145,059 (95% CI, $106,703 to $233,225).Bevacizumab was not found to be cost effective at its listed price, based on results from the MAX trial.en
dc.language.isoenen
dc.subject.otherBevacizumaben
dc.subject.otherCanceren
dc.subject.otherColorectalen
dc.subject.otherCosten
dc.subject.otherEffectivenessen
dc.subject.otherMAXen
dc.subject.otherAntibodies, Monoclonal, Humanized.administration & dosageen
dc.subject.otherAntimetabolites, Antineoplastic.administration & dosageen
dc.subject.otherAntineoplastic Combined Chemotherapy Protocols.adverse effects.economics.therapeutic useen
dc.subject.otherAustraliaen
dc.subject.otherColorectal Neoplasms.drug therapy.economics.pathologyen
dc.subject.otherDeoxycytidine.administration & dosage.analogs & derivativesen
dc.subject.otherDisease-Free Survivalen
dc.subject.otherFemaleen
dc.subject.otherFluorouracil.administration & dosage.analogs & derivativesen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMitomycin.economicsen
dc.subject.otherQuality of Lifeen
dc.subject.otherTreatment Outcomeen
dc.titleThe cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean journal of cancer (Oxford, England : 1990)en
dc.identifier.affiliationThe Queen Elizabeth Hospital, 28 Woodville Rd, Woodville, SA 5011, Australiaen
dc.identifier.affiliationAustin Health, PO Box 5555, Heidelberg, VIC 3084, Australiaen
dc.identifier.affiliationSchool of Public Health, The University of Sydney, Edward Ford Building, NSW 2006, Australiaen
dc.identifier.affiliationDepartment of Oncology, University of Melbourne, Australiaen
dc.identifier.affiliationThe University of Adelaide, Australiaen
dc.identifier.affiliationPeter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, VIC 8006, Australiaen
dc.identifier.affiliationNHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 2050, Australiaen
dc.identifier.doi10.1016/j.ejca.2013.09.028en
dc.description.pages535-43en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24215848en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Feb 6, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.